公告显示，本次股权转让定价以专业评估为依据。截至2025年8月31日评估基准日，阿依达公司股东全 部权益评估值为27万元，对应涪陵药厂所持40%股权评估值10.8万元，该价格将作为首次挂牌转让底 价，最终成交金额以实际交易结果为准。值得注意的是，阿依达公司近年经营承压，截至2025年8月31 日，其资产总额1.23亿元，负债总额1.52亿元，净资产为-2896万元；2025年1-8月实现营业收入1151万 元，净利润亏损1678万元，2024年全年净利润亏损780万元。 从公司基本面来看，太极集团聚焦主业的战略已显成效。2025年前三季度，公司实现营业收入80.88亿 元，归母净利润1.66亿元，基本每股收益0.30元，资产总额达142.22亿元，形成稳健经营格局。 太极集团表示，未来将持续深化主业聚焦战略，稳步推进"两资两非"清理工作，不断提升经营质量与管 理效率，为全体股东创造更大价值。 作为转让方，涪陵药厂对阿依达公司的长期股权投资初始成本为4750万元，但由于标的公司持续亏损， 截至2024年12月31日，该笔投资按权益法核算的账面价值已减记为0。太极集团明确表示，本次转让不 会对公司当期损益产生重大 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600129 证券简称：太极集团 公告编号：2025-091 重庆太极实业（集团）股份有限公司关于全资子公司拟公开挂牌转让参股公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 重庆太极实业（集团）股份有限公司（以下简称：公司）全资子公司太极集团重庆涪陵制药厂有限公司 （以下简称：涪陵药厂）持有重庆阿依达太极泉水股份有限公司(以下简称:阿依达公司)40%的股份，该 公司拟通过挂牌转让方式对外公开转让上述股份。 本次交易将通过公开挂牌方式转让，交易对方存在不确定性，尚不确定是否构成关联交易。 本次交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。本次交易事项已经公司第十 届董事会第三十四次会议审议通过。 根据《上海证券交易所股票上市规则》，本次交易在董事会审批权限范围内，无需提交公司股东大会审 议。 风险提示：本次交易将通过公开挂牌的方式转让，交易能否达成 及最终成交价格均存在不确定性。公 司将密切关注本次交易的进展情 况，严格按 ...

证券日报网讯12月23日，太极集团（600129）在互动平台回答投资者提问时表示，公司下属子公司太极 集团海南医药研究有限公司、海南太极海洋药业有限公司及海南太极医疗养生有限公司注册地均为海南 省，相关情况敬请关注公司发布的公告。 ...

太极集团12月23日公告，公司全资子公司涪陵药厂持有重庆阿依达太极泉水股份有限公司40%股份，拟 通过挂牌转让方式对外公开转让上述股份。 ...

Group 1 - Shareholder of Okoyi plans to reduce holdings by up to 1.89% of the company's shares, amounting to a maximum of 3 million shares due to personal funding needs [1] - Tianchuang Fashion is planning a change in control, leading to continued suspension of its stock trading, expected to last no more than 3 trading days [2] - China Electric Power Construction Company reported a new contract amount of 10,317.55 billion yuan for the first 11 months of 2025, a year-on-year decrease of 1.65% [3] Group 2 - Pilin Bio's wholly-owned subsidiary received approval for a clinical trial of a drug, indicating progress in its product development [4] - Yihong Medical obtained two medical device registration certificates for diagnostic kits, enhancing its product portfolio [5] - Aohong Electronics plans to use up to 450 million yuan of idle fundraising for cash management, targeting safe and liquid financial products [6] Group 3 - China Electric Power Construction signed a contract worth approximately 6.626 billion yuan for a natural gas booster station project in Turkey, with a construction period of about 55 months [7] - Baosheng Co. won a bid for a power cable project in Singapore, valued at around 1.2 billion yuan, marking the largest overseas order in its history [8] - *ST Xinyan's stock will resume trading on December 24, 2025, following a capital increase plan that will raise its total share capital to 3.29 billion shares [9] Group 4 - Ningbo Construction's subsidiary signed a construction contract worth 428 million yuan for an engineering project with a duration of 990 days [11] - Lianhuan Pharmaceutical's subsidiary received approval for a drug that passed the consistency evaluation for generic drugs, enhancing its market competitiveness [12] - Zhongjie Automotive received a project designation for a new electric air conditioning compressor, with expected sales of approximately 29.86 million USD over its lifecycle [13] Group 5 - Biopharmaceuticals' major shareholder plans to increase holdings by 50 million to 100 million yuan, indicating confidence in the company's future [14] - Haizheng Pharmaceutical's subsidiary received approval for a veterinary drug product, expanding its product offerings in the animal health sector [15] - *ST Songfa's subsidiary signed contracts for the construction of 8 vessels, with a total contract value between 200 million to 400 million USD [16] Group 6 - Shandong Pharmaceutical Glass announced the resignation of its chairman due to age reasons, indicating a potential leadership transition [17] - Xinno Wei's subsidiary received approval for a clinical trial of a monoclonal antibody drug, indicating advancements in its drug development pipeline [18] - Ningbo Huaxiang's subsidiary secured an order for robot joints, expected to positively impact future business performance [19][20] Group 7 - China Resources Double Crane's subsidiary received approval for a clinical trial of a drug aimed at treating a genetic eye disease, reflecting ongoing R&D efforts [21] - Huaxin Technology's shareholders set a transfer price of 56.69 yuan per share for a block of shares, indicating active shareholder engagement [22] - Xinhua Net announced the resignation of its president due to job relocation, suggesting potential changes in management [23] Group 8 - Taiji Group plans to transfer a 40% stake in a subsidiary to focus on its core pharmaceutical business, enhancing operational efficiency [24] - Huaxin Construction's shareholder plans to increase holdings by 200 million to 400 million yuan, reflecting confidence in the company's prospects [25] - Dongjie Intelligent is planning to issue shares and cash for asset acquisition, with stock trading suspended until further notice [26] Group 9 - Wanrun New Energy was designated as a delivery warehouse for lithium carbonate futures, indicating its strategic position in the market [27] - Prolo Pharmaceutical's subsidiary received a drug registration certificate for an influenza treatment, expanding its product range [28] - Saiwu Technology invested 5 million yuan in a private equity fund focused on smart vehicles and energy innovation, indicating strategic investment in growth sectors [29] Group 10 - Bohui Innovation's subsidiary received approval for a clinical trial of an immunoglobulin drug, indicating progress in its product development [30] - Bohui Innovation's subsidiary also received a drug registration certificate for a coagulation factor product, enhancing its therapeutic offerings [31] - Hanghua Co. plans to allocate 146 million yuan of surplus fundraising for a new green printing materials project, reflecting a commitment to sustainability [32] Group 11 - Nova Star Cloud obtained a loan commitment letter from a bank for a share repurchase plan, indicating financial support for its capital management strategy [33] - Jimin Health established a joint venture for technology innovation, indicating a strategic move to enhance its technological capabilities [34] - Huili Pharmaceutical received a drug registration certificate for a medication used in treating digestive ulcers, expanding its product portfolio [35]

本次交易不构成《上市公司重大资产重组管理办法》规定的重大 资产重组。本次交易事项已经公司第十届董事会第三十四次会议审议 通过。 根据《上海证券交易所股票上市规则》，本次交易在董事会审批 权限范围内，无需提交公司股东大会审议。 重庆太极实业（集团）股份有限公司（以下简称：公司）全资子 公司太极集团重庆涪陵制药厂有限公司（以下简称：涪陵药厂）持有 重庆阿依达太极泉水股份有限公司(以下简称:阿依达公司)40%的股 份，该公司拟通过挂牌转让方式对外公开转让上述股份。 本次交易将通过公开挂牌方式转让，交易对方存在不确定性，尚 不确定是否构成关联交易。 证券代码：600129 证券简称：太极集团 公告编号：2025-091 重庆太极实业（集团）股份有限公司 关于全资子公司拟公开挂牌转让 参股公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： 风险提示：本次交易将通过公开挂牌的方式转让，交易能否达成 及最终成交价格均存在不确定性。公司将密切关注本次交易的进展情 况，严格按照《上海证券交易所股票上市规则》等法律法 ...

2024年1至12月份，太极集团的营业收入构成为：工业占比56.82%，商业占比54.42%，中药材资源占比 8.5%，大健康及国际占比3.72%，其他业务占比1.22%。 截至发稿，太极集团市值为100亿元。 每经AI快讯，太极集团（SH 600129，收盘价：18.19元）12月23日晚间发布公告称，为聚焦主业，加 大"两资两非"企业清理，提升管理效能，公司全资子公司涪陵药厂拟将持有重庆阿依达太极泉水股份有 限公司（简称：阿依达公司）40%的股份通过挂牌转让方式对外公开出让，本次挂牌转让价格以评估值 10.8万元为依据，首次公开挂牌转让价格为10.8万元，最终交易金额以实际成交价格为准。 每经头条（nbdtoutiao）——地产"优等生"受困20亿元到期债务，首次债务展期仍在博弈，明年还有超 百亿元公开债到期 （记者 王晓波） ...

格隆汇12月23日丨太极集团(600129.SH)公布，为聚焦主业，加大"两资两非"企业清理，提升管理效 能，公司全资子公司涪陵药厂拟将持有阿依达公司40%的股份通过挂牌转让方式对外公开出让，本次挂 牌转让价格以评估值10.8万元为依据，首次公开挂牌转让价格为10.8万元，最终交易金额以实际成交价 格为准。 ...

太极集团公告称，为聚焦主业，全资子公司涪陵药厂拟公开挂牌转让所持阿依达公司40%股份，首次挂 牌价10.8万元。本次交易不构成重大资产重组，已获董事会通过，无需股东大会审议。阿依达公司2025 年1 - 8月营收1151万元，净利润 - 1678万元，截至8月31日净资产 - 2896万元，评估后净资产为27万元。 交易对方和最终价格不确定，能否成功转让也不确定，公司将及时披露进展。 ...

智通财经APP讯，太极集团(600129.SH)发布公告，为聚焦主业，加大"两资两非"企业清理，提升管理效 能，公司全资子公司涪陵药厂拟将持有阿依达公司40%的股份通过挂牌转让方式对外公开出让，本次挂 牌转让价格以评估值10.8万元为依据，首次公开挂牌转让价格为10.8万元，最终交易金额以实际成交价 格为准。 ...